No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Zhou, Si wei ^a   Huang, Yuan yuan ^b   Wei, Ying ^a   Jiang, Zhi min ^a   Zhang, Yuan dong ^c   Yang, Qiong ^a   Xie, De rong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAS PROTEINS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84870578675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050925     Document Type: Article

References (24)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global Cancer Statistics. CA Cancer J Clin 61: 134.
2. Wolpin BM, Mayer R, (2008) Systemic treatment of colorectal cancer. Gastroenterology 134: 1296-1210.
3. O'Neil BH, Goldberg RM, (2008) Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist 13: 1074-1083.
4. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med 360: 1408-1417.
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 351: 337-345.
6. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
8. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28: 493-508.
9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
10. Sterne JA, Egger M, Smith GD, (2001) Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-5.
11. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
12. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.
13. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, et al. (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377: 2103-14.
14. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, et al. (2012) Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. J Clin Oncol. Published online before print. Available: http://jco.ascopubs.org/content/early/2012/03/27/JCO.2011.38.0915.long.
15. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
16. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2011) Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 29 (15s): abstr 3510.
17. US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry: Clinical trial endpoints for the approval of cancer drugs and biologics. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
18. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, et al. (2009) Synergistic activity of the Src Family kinase Inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69: 3842-3849.
19. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, et al. (2007) Epidermal Growth Factor Receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67: 8240-8247.
20. Ibrahim EM, Zekri JM, Bin Sadiq BM, (2010) Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis 25: 713-721.
21. Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL, (2011) A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 47: 1343-1354.
22. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
23. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572.
24. Bria E, Gralla R, Raftopoulos H, Giannarelli D (2007) Comparing two methods of meta-analysis in clinical research- individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs). J Clin Oncol 25(18s): abstr 6512.